| Not Yet Recruiting | A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hep Hepatocellular Carcinoma (HCC) | Phase 2 / Phase 3 | 2026-03-01 |
| Active Not Recruiting | A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors Liver Cancer | Phase 1 | 2025-07-01 |
| Recruiting | A Study of SH009 Injection in Patients With Advanced Solid Tumors. Liver Cancer (Locally Advanced or Metastatic), Lung Cancer (NSCLC), Head and Neck Cancer Squamous Cell Carcinoma | Phase 1 | 2025-05-16 |
| Recruiting | SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutat Non-small Cell Lung Cancer | Phase 3 | 2023-05-11 |
| Unknown | A Study to Investigate Safety and Tolerability of SH3765 Tablet in Patients With Advanced Malignant Tumor Advanced Malignant Tumor | Phase 1 | 2021-09-01 |
| Unknown | The Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SH-1028 Healthy Male Volunteers | Phase 1 | 2021-04-06 |
| Unknown | A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2021-04-02 |
| Unknown | A Phase 1 Study of SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous Leukemia Acute Myelogenous Leukemia | Phase 1 | 2020-08-04 |
| Unknown | A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma Peripheral T Cell Lymphoma | Phase 2 | 2020-08-01 |
| Unknown | A Study to Investigate Safety and Tolerability of SH3051 Capsule in Patients With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2020-05-14 |
| Completed | The Absorption, Metabolism and Excretion of [14C]SH-1028 in Chinese Healthy Male Volunteers Healthy Male Volunteers | Phase 1 | 2020-05-13 |
| Unknown | Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZ Follicular Lymphoma(FL), Marginal Zone Lymphoma(MZL) | Phase 2 | 2020-05-09 |
| Unknown | A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lun Non-Small Cell Lung Cancer | Phase 3 | 2020-01-31 |
| Unknown | A Food-Effect Study of SHC014748M in Healthy Subjects Healthy Volunteer | Phase 1 | 2019-07-01 |
| Unknown | Pharmacokinetic Study of SH-1028 Tablets in Healthy Subjects Under Fasting and Fed Conditions Healthy Volunteer | Phase 1 | 2019-07-01 |
| Unknown | SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepat Hepatitis C, Chronic | Phase 2 / Phase 3 | 2019-03-29 |
| Unknown | A Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLC Non-Small Cell Lung Cancer | Phase 2 | 2019-03-01 |
| Completed | A Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects Drug Interactions | Phase 1 | 2018-11-19 |
| Unknown | Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer Advanced Solid Cancer | Phase 1 | 2018-09-13 |
| Unknown | Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignan Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), B-Cell Non-Hodgkin Lymphomas(NHL) | Phase 1 | 2018-09-07 |
| Completed | Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection HCV Infection | Phase 1 | 2018-07-07 |
| Unknown | Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC Non-small Cell Lung Cancer | Phase 1 | 2018-04-25 |